An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

PRISTIQ®

Drug Information Related Patent

Hold Company

PF PRISM CV

Learn More

Dosage and Administration

TABLET, EXTENDED RELEASE;ORAL

Specification

EQ 50MG BASE; EQ 100MG BASE; EQ 25MG BASE

Indication

PRISTIQ® is suitable for adult major depressive disorder (MDD) treatment.

Use

Instructions for Use

API

DESVENLAFAXINE SUCCINATE

API Structure

We Supply

DESVENLAFAXINE SUCCINATE

Note:

Facility GMP
USMF/FDA

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
8269040	2027/7/5

API Patent

Patent No	Expiration Date
8269040	2027/7/5

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION